GleamWall
中文EN

BBIO BridgeBio Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1743881 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY167.3%
TTM net income YoY29.0%
TTM EPS YoY28.0%
Revenue 3-yr CAGR364.6%
Net income 3-yr CAGR—

Margins

Gross margin94.3%
Operating margin-38.5%
Net margin-59.8%
FCF margin-39.1%
EBITDA margin-38.0%

Returns

ROE—
ROA-35.8%
ROIC (approx.)—
Asset turnover0.60x

Leverage & solvency

Liabilities / assets176.5%
Debt / equity—
Current ratio2.09x
Interest coverage-7.13x

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-12.5%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q2*2026-06-302026Q1*2026-03-312025Q4*2025-12-312025Q32025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-31
Income statement
Revenue$353.17M$243.68M$194.51M$154.18M$120.70M$110.56M$116.63M$5.88M
Cost of revenue$20.45M$15.05M$9.94M$8.11M$6.56M$3.65M$2.64M$2.08M
Gross profit$332.72M$228.63M$184.58M$146.07M$114.14M$106.91M$113.99M$3.80M
R&D expense$143.51M$149.45M$126.64M$116.42M$112.87M$111.23M$111.43M$130.35M
SG&A expense$200.85M$186.26M$163.90M$158.09M$137.62M$129.15M$106.36M$94.78M
Operating income-$11.64M-$107.08M-$105.96M-$139.56M-$145.20M-$134.28M-$104.37M-$226.03M
Interest expense$13.26M$13.28M$12.94M$11.64M$11.74M$11.61M$18.12M$21.52M
Pretax income-$59.27M-$155.89M—-$194.75M-$186.48M-$181.66M—-$266.24M
Income tax$1.23M$0—-$120,000-$1.54M$2.10M$0$1.15M
Net income-$56.71M-$152.22M-$164.04M-$192.86M-$182.74M-$181.90M-$167.42M-$265.05M
EBITDA-$10.57M-$106.03M-$104.77M-$138.13M-$143.80M-$132.96M-$103.09M-$224.66M
EPS (basic)-0.42-0.78-0.84—-0.95-0.95-0.88—
EPS (diluted)-0.42-0.78-0.84—-0.95-0.95-0.88—
Weighted avg. shares (diluted)196.03M195.79M194.79M—191.85M190.52M190.15M—
Balance sheet
Cash & equivalents$1.53B$677.91M$879.89M$570.12M$642.95M$748.95M$540.60M$681.10M
Short-term investments$5.49M$42.25M$60.30M$17.36M$2.99M$7.94M—$0
Receivables$375.09M$254.48M$205.23M$139.44M$116.52M$76.87M$115.27M$4.72M
Inventory$59.72M$52.84M$32.98M$26.75M$24.53M$18.28M$3.95M$0
Current assets$2.04B$1.09B$1.24B$797.75M$839.38M$912.28M$695.17M$720.69M
PP&E, net$5.04M$5.23M$4.94M$5.37M$5.83M$6.11M$6.70M$7.01M
Intangibles$25.92M$26.64M$27.36M$28.08M$28.80M$29.51M$27.80M$23.93M
Total assets$2.16B$1.22B$1.37B$936.02M$998.25M$1.08B$881.64M$919.34M
Current liabilities$977.24M$890.65M$816.37M$287.97M$216.60M$175.85M$152.10M$154.40M
Long-term debt$2.63B$2.65B$2.65B$2.01B$2.01B$0$0$437.34M
Total debt$2.63B$2.65B$2.65B$2.01B$2.01B$0$0$437.34M
Total liabilities$3.82B$3.72B$3.64B$3.01B$2.92B$2.86B$2.52B$2.38B
Shareholders' equity-$1.66B-$2.52B-$2.28B-$2.09B-$1.93B-$1.79B-$1.65B-$1.47B
Net debt$1.10B$1.97B$1.77B$1.44B$1.36B-$748.95M-$540.60M-$243.76M
Shares outstanding196.00M195.28M195.71M194.77M192.63M191.16M189.83M190.04M
Cash flow statement
Operating cash flow-$44.17M-$71.10M-$197.28M-$56.42M-$109.57M-$80.68M-$199.24M-$195.33M
Capital expenditure$290,000$443,000$69,000$33,000$470,000$594,000$0$47,000
Free cash flow-$44.46M-$71.54M-$197.35M-$56.45M-$110.04M-$81.28M-$199.24M-$195.37M
Investing cash flow$36.61M$17.89M-$42.73M-$14.35M$4.46M-$13.00M-$1.59M-$3.24M
Financing cash flow$863.01M-$148.77M$549.89M-$2.18M-$894,000$302.04M$60.33M$473.93M
Depreciation & amortization$1.07M$1.05M$1.19M$1.44M$1.40M$1.32M$1.28M$1.37M
Stock-based compensation$39.86M$44.52M$33.24M$34.64M$35.26M$37.34M$25.88M$30.13M
Share buybacks$42.50M$127.50M$82.50M$0$0$0$48.28M$0

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.